In contrast, on day 15, while AlCVCT26@D‐Gel still exerted no impact on T cell activation due to low antigenic relevance of CT26 cell‐derived vaccines to 4T1 tumors,[7, 8, 14] ZCVCT26@D‐Gel significantly expanded the frequencies of tumor‐infiltrating CD8+CD3+ T cells, CD4+CD3+ T, and IFN‐γ‐secreting T cells (Figure 5E). The gene discussed is CD8A; the disease is neoplasm.